Get the Stockscreener App
6.04
4.13%
-0.26
After Hours:
6.00
-0.04
-0.66%
Tango Therapeutics Inc stock is traded at $6.04, with a volume of 2.48M.
It is down -4.13% in the last 24 hours and up +17.97% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$6.30
Open:
$6.23
24h Volume:
2.48M
Relative Volume:
0.86
Market Cap:
$654.70M
Revenue:
$42.51M
Net Income/Loss:
$-116.49M
P/E Ratio:
-5.3929
EPS:
-1.12
Net Cash Flow:
$-120.82M
1W Performance:
-10.52%
1M Performance:
+17.97%
6M Performance:
+102.68%
1Y Performance:
-38.68%
1-Day Range:
$5.80
$6.2956
1-Week Range:
$5.595
$7.105
52-Week Range:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.04 | 682.88M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
What machine learning models say about Tango Therapeutics Inc.Early Entry Planner for Swing Candidates - Newser
Can Tango Therapeutics Inc. stock recover from recent declineFree Entry Alert Based on Volume Spikes - Newser
Risk vs reward if holding onto Tango Therapeutics Inc.Free Weekly Return Pick Forecast Reports - Newser
Will Tango Therapeutics Inc. outperform the marketSwing Reversal Forecast Based on Patterns - Newser
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade - sharewise.com
How high can Tango Therapeutics Inc. stock price go in 2025Swing Reversal Forecast Based on Patterns - Newser
Will Tango Therapeutics Inc. stock benefit from interest rate changesProven Trading System with Consistent Gains - Newser
Applying Elliott Wave Theory to Tango Therapeutics Inc.Sector Rotation Outlook With Historical Summary - Newser
Tango Therapeutics Inc. Moves Into Overbought Range Analysts CautiousEntry Alert With Low Drawdown Strategy Noted - metal.it
Will Tango Therapeutics Inc. Reverse From Oversold ConditionsWeekly Watchlist of High Movers Released - metal.it
Tango Therapeutics Inc. recovery potential after sell offAI Enhanced Strategy for Portfolio Growth - Newser
Published on: 2025-07-29 16:59:33 - Newser
how tango therapeutics inc. stock performs during market volatilityPattern Breakout Tracker with Screener Tools - Newser
Price action breakdown for Tango Therapeutics Inc.Pattern Breakout Prediction for Short Term - Newser
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
How did TNGX's Q1 2025 EPS forecast compare to past trends? - AInvest
Does Tango Therapeutics Inc. stock perform well during market downturnsTop Growth Trend Scanner With High Returns - jammulinksnews.com
Tango Therapeutics Inc. Company Revenue and Profit Trends: A Deep Dive Weekly Growth Portfolio Performance Summary - Newser
What institutional investors are buying Tango Therapeutics Inc. stockTop Growth Opportunities For Fast Growth - jammulinksnews.com
Price action breakdown for Tango Therapeutics Inc. Free Beginner Friendly Stock Selection Guide - Newser
How does Tango Therapeutics Inc. generate profit in a changing economyMarket-beating performance - jammulinksnews.com
How does Tango Therapeutics Inc. compare to its industry peersUnlock daily market insights for better trades - jammulinksnews.com
What are Tango Therapeutics Inc. company’s key revenue driversUnlock exclusive stock analysis for investors - jammulinksnews.com
What are analysts’ price targets for Tango Therapeutics Inc. in the next 12 monthsNavigate market shifts with confidence - jammulinksnews.com
What are the latest earnings results for Tango Therapeutics Inc.Invest confidently with real-time data - jammulinksnews.com
Should I hold or sell Tango Therapeutics Inc. stock in 2025Explosive capital appreciation - jammulinksnews.com
Tango Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveFree Stock Trading Signals - Newser
What drives Tango Therapeutics Inc. stock priceMassive portfolio appreciation - Autocar Professional
Tango Therapeutics Inc. Stock Analysis and ForecastExceptional earning trajectories - PrintWeekIndia
Will Tango Therapeutics Inc. stock benefit from AI tech trendsSuperior capital gains - jammulinksnews.com
Is Tango Therapeutics Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):